Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Alberto A, Chiappori"'
Autor:
Hilal Ozakinci, MD, Aileen Y. Alontaga, PhD, Pedro Cano, MD, John M. Koomen, PhD, Bradford A. Perez, MD, Amer A. Beg, PhD, Alberto A. Chiappori, MD, Eric B. Haura, MD, Theresa A. Boyle, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 11, Pp 100723- (2024)
Introduction: The translation of gene expression profiles of SCLC to clinical testing remains relatively unexplored. In this study, gene expression variations in SCLC were evaluated to identify potential biomarkers. Methods: RNA expression profiling
Externí odkaz:
https://doaj.org/article/ea0254e38bb7448e97135d59c5c6d059
Autor:
Toshihiko Doi, John A Thompson, Omid Hamid, Adi Diab, Siwen Hu-Lieskovan, Jeffrey Chou, Jeffrey S Wasser, Patrick A Ott, Jean-Philippe Spano, Willeke Ros, Alison Forgie, Wenjing Yang, Ferry A L M Eskens, Alberto A Chiappori, Eric Angevin, Naiyer A Rizvi, Cen Guo, Anthony B El-Khoueiry
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 10 (2022)
Background Ivuxolimab (PF-04518600) and utomilumab (PF-05082566) are humanized agonistic IgG2 monoclonal antibodies against OX40 and 4-1BB, respectively. This first-in-human, multicenter, open-label, phase I, dose-escalation/dose-expansion study expl
Externí odkaz:
https://doaj.org/article/ccd14bbe12da44b9bec3de265e3da2d8
Autor:
Theresa A. Boyle, Gwendolyn P. Quinn, Matthew B. Schabath, Teresita Muñoz‐Antonia, James J. Saller, Luisa F. Duarte, Laura S. Hair, Jamie K. Teer, Derek Y. Chiang, Rebecca Leary, Connie C. Wong, Alexander Savchenko, Angad P. Singh, LaSalette Charette, Kate Mendell, Gullu Gorgun, Scott J. Antonia, Alberto A. Chiappori, Benjamin C. Creelan, Jhanelle E. Gray, Eric B. Haura
Publikováno v:
Cancer Medicine, Vol 9, Iss 1, Pp 225-237 (2020)
Abstract Background For the advancement of cancer research, the collection of tissue specimens from drug‐resistant tumors after targeted therapy is crucial. Although patients with lung cancer are often provided targeted therapy, post‐therapy spec
Externí odkaz:
https://doaj.org/article/82ae3eb5e1ff40e2b1ca8ba0ac5ee571
Autor:
Bhaswati Sarcar, Nicholas T. Gimbrone, Gabriela Wright, Lily L. Remsing Rix, Edna R. Gordian, Uwe Rix, Alberto A. Chiappori, Gary W. Reuther, Pedro G. Santiago‐Cardona, Teresita Muñoz‐Antonia, William Douglas Cress
Publikováno v:
FEBS Open Bio, Vol 9, Iss 10, Pp 1689-1704 (2019)
Lung cancer patients with mutations in epidermal growth factor receptor (EGFR) benefit from treatments targeting tyrosine kinase inhibitors (TKIs). However, both intrinsic and acquired resistance of tumors to TKIs are common, and EGFR variants have b
Externí odkaz:
https://doaj.org/article/6e8351e2101b44f9952c7a2874a030c7
Autor:
Dung-Tsa Chen, Wenyaw Chan, Zachary J Thompson, Ram Thapa, Amer A Beg, Andreas N Saltos, Alberto A Chiappori, Jhanelle E Gray, Eric B Haura, Trevor A Rose, Ben Creelan
Publikováno v:
PLoS ONE, Vol 16, Iss 7, p e0252041 (2021)
RationaleRecent studies have discovered several unique tumor response subgroups outside of response classification by Response Evaluation Criteria for Solid Tumors (RECIST), such as mixed response and oligometastasis. These subtypes have a distinctiv
Externí odkaz:
https://doaj.org/article/659848f0970b4b5e8a041e80db5248b8
Autor:
Scott Antonia, Luigi Manenti, Felipe K. Hurtado, Mehreteab Aregay, Erick Morris, Liza Morgan, Julio Castro, Theresa A. Boyle, Amer A. Beg, Dung Tsa Chen, Zhihua Chen, Margaret L. Barlow, Ram Thapa, Eric B. Haura, Jhanelle E. Gray, Tawee Tanvetyanon, Ben Creelan, Alberto A. Chiappori
Supplementary Data from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::132a17999cf561e16d852c6c6bd2e740
https://doi.org/10.1158/1078-0432.22482872
https://doi.org/10.1158/1078-0432.22482872
Autor:
Scott Antonia, Luigi Manenti, Felipe K. Hurtado, Mehreteab Aregay, Erick Morris, Liza Morgan, Julio Castro, Theresa A. Boyle, Amer A. Beg, Dung Tsa Chen, Zhihua Chen, Margaret L. Barlow, Ram Thapa, Eric B. Haura, Jhanelle E. Gray, Tawee Tanvetyanon, Ben Creelan, Alberto A. Chiappori
Supplementary Figure from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b5cd0e8a30096fe605803c93a7c6ea5
https://doi.org/10.1158/1078-0432.22482863.v1
https://doi.org/10.1158/1078-0432.22482863.v1
Autor:
Scott Antonia, Luigi Manenti, Felipe K. Hurtado, Mehreteab Aregay, Erick Morris, Liza Morgan, Julio Castro, Theresa A. Boyle, Amer A. Beg, Dung Tsa Chen, Zhihua Chen, Margaret L. Barlow, Ram Thapa, Eric B. Haura, Jhanelle E. Gray, Tawee Tanvetyanon, Ben Creelan, Alberto A. Chiappori
Purpose:The adenosine 2A receptor (A2AR) mediates the immunosuppressive effects of adenosine in the tumor microenvironment and is highly expressed in non–small cell lung cancer (NSCLC). Taminadenant (PBF509/NIR178) is an A2AR antagonist able to rea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c600f5561f5796c03303f29e1f1e770
https://doi.org/10.1158/1078-0432.c.6531020
https://doi.org/10.1158/1078-0432.c.6531020
Autor:
Casey L. Liveringhouse, Kujtim Latifi, Amalin G. Asous, Nghi B. Lam, Stephen A. Rosenberg, Thomas J. Dilling, Gretchen V. MacMillan, Alberto A. Chiappori, Eric B. Haura, Ben Creelan, Jhanelle E. Gray, Tawee Tanvetyanon, Michael R. Shafique, Andreas N. Saltos, Ashley A. Weiner, Jeffrey Clarke, Christopher R. Kelsey, Sungjune Kim, James J. Caudell, Trevor A. Rose, Jose R. Conejo-Garcia, Jiannong Li, Michael J. Schell, Scott J. Antonia, Bradford A. Perez
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81bd97d6cc1e17fe508887e3fa0aa520
https://doi.org/10.1016/j.ijrobp.2023.01.006
https://doi.org/10.1016/j.ijrobp.2023.01.006
Autor:
Omid Hamid, Alberto A Chiappori, John A Thompson, Toshihiko Doi, Siwen Hu-Lieskovan, Ferry A L M Eskens, Willeke Ros, Adi Diab, Jean-Philippe Spano, Naiyer A Rizvi, Jeffrey S Wasser, Eric Angevin, Patrick A Ott, Alison Forgie, Wenjing Yang, Cen Guo, Jeffrey Chou, Anthony B El-Khoueiry
Publikováno v:
Journal for ImmunoTherapy of Cancer, 10(10):e005471. BioMed Central Ltd.
BackgroundIvuxolimab (PF-04518600) and utomilumab (PF-05082566) are humanized agonistic IgG2 monoclonal antibodies against OX40 and 4-1BB, respectively. This first-in-human, multicenter, open-label, phase I, dose-escalation/dose-expansion study explo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa1dda7e7d3a12439bbe12c6f5cc93b2
http://www.scopus.com/inward/record.url?scp=85140857731&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85140857731&partnerID=8YFLogxK